Citations (2)
Keep up to date with the latest research on this topic with citation updates for this article.
OncoImmunology
Volume 10, 2021 - Issue 1
Research Article
An Open–Label, Randomized, Multi–Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin–2) and Ipilimumab (Yervoy) in Patients with Metastatic Melanoma
Merve Hasanova Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas Md Anderson Cancer Center, Houston, USA
https://orcid.org/0000-0002-6102-4917View further author information
https://orcid.org/0000-0002-6102-4917View further author information, , William H. Sharfmanc Department of Medical Oncology and Dermatology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Lutherville, USAhttps://orcid.org/0000-0001-7766-249XView further author information
https://orcid.org/0000-0001-7766-249XView further author information, Bret Tabackd Department of Surgery, Division of Breast Surgery, New York-Presbyterian/Columbia University Medical Center, New York, USAhttps://orcid.org/0000-0003-3440-5316View further author information
https://orcid.org/0000-0003-3440-5316View further author information, Lee D. Cranmere University of Arizona Cancer Center, Tucson, Az, Usa. Present Affiliation and Contact: Division of Medical Oncology, Department of Medicine, University of Washington Medical Center, and Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, USAhttps://orcid.org/0000-0002-7789-5442View further author information
https://orcid.org/0000-0002-7789-5442View further author information, Gregory A Danielsf Division of Hematology-Oncology, University of California San Diego, La Jolla, USAhttps://orcid.org/0000-0001-9087-8009View further author information
https://orcid.org/0000-0001-9087-8009View further author information, , Sigrun Hallmeyerh Department of Hematology-Oncology, Advocate Medical Group, Park Ridge, USAhttps://orcid.org/0000-0001-5342-2846View further author information
https://orcid.org/0000-0001-5342-2846View further author information, Mohammed Milhemi Section of Oncology, Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, USAhttps://orcid.org/0000-0003-4663-6824View further author information
https://orcid.org/0000-0003-4663-6824View further author information, Lynn Feunj Department of Medical Oncology, University of Miami Health System, Miami, USAhttps://orcid.org/0000-0002-7310-2601View further author information
https://orcid.org/0000-0002-7310-2601View further author information, Ralph Haukek Nebraska Cancer Specialists, Omaha, USAhttps://orcid.org/0000-0002-0243-7279View further author information
https://orcid.org/0000-0002-0243-7279View further author information, Gary Doolittlel Division of Medical Oncology, Department of Medicine, University of Kansas Medical Center, Kansas City, USAhttps://orcid.org/0000-0002-9141-449XView further author information
https://orcid.org/0000-0002-9141-449XView further author information, & Sapna Patela Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas Md Anderson Cancer Center, Houston, USACorrespondence[email protected]
https://orcid.org/0000-0003-1339-1517View further author information
https://orcid.org/0000-0003-1339-1517View further author information show all